Skip to content
DraconiticResearch
Search Sources API
181,716 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BYMolecular genetics & genomic medicine

Genotypic-Phenotypic Correlations in Non-HbE β-Thalassemia Intermedia: A Geographic Systematic Review.

4 affiliations
  1. 1Department of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
  2. 2NK Ceylon Institute of Medical Research, Negombo, Sri Lanka.
  3. 3Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
  4. 4University Medical Unit, Colombo North Teaching Hospital, Ragama, Sri Lanka.

Abstract

Background

β-thalassemia intermedia (β-TI), now more commonly classified within the spectrum of non-transfusion-dependent thalassemia (NTDT), is a clinically heterogeneous disorder in which disease severity is determined not only by β-globin mutations but also by co-inherited genetic modifiers that vary across populations. These include α-globin gene alterations, fetal haemoglobin (HbF)-inducing polymorphisms, and other regulatory loci that influence globin chain balance.Methods

A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed was searched from inception to May 2026, supplemented by citation tracking and manual screening. Studies reporting genotype-phenotype correlations in β-TI were included. Data were synthesized qualitatively by geographic region.Results

Twenty-one studies were included. The available evidence suggests Mediterranean populations are primarily influenced by mild β-globin mutations. In Middle Eastern populations, HbF-inducing polymorphisms, particularly the XmnI variant, played a prominent role, often mitigating severe genotypes. Among the included studies, Asian populations exhibited the greatest molecular heterogeneity, with α-globin gene dosage alterations, including triplication, contributing substantially to disease expression.Conclusion

The available evidence suggests regional differences in the contribution of genetic modifiers to the β-thalassemia intermedia phenotype. Recognition of these patterns may improve understanding of genotype-phenotype variability and may help inform future approaches to diagnosis, prognostication, and individualized therapeutic strategies.

Related

  1. Latent Correlations Between Longitudinal Systemic Complement Factors and Geographic Atrophy Growth Rate
    Talisa E. de Carlo Forest, Nathan C. Grove, Nicholas Cordaro +12
    Investigative Ophthalmology & Visual SciencePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Intraspinal abnormalities in MRI-evaluated congenital scoliosis: a systematic review and meta-analysis of prevalence, geographic variation, vertebral anomaly patterns, and Cobb angle.
    Nizar Algarni, Khalid Alrasheed, Faisal Alkhunein +3
    North American Spine Society journalPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. OphthoEvidence Report: Comparative effects of treatments for geographic atrophy secondary to age-related macular degeneration: A protocol for a living systematic review and network meta-analysis
    Maryam Ghadimi, Housne Begum, Dena Zeraatkar +9
    PLOS OnePeer-reviewedCC BY 4.0Full textImmunologyPhysiologyPLOS
  4. SF3B1-mutated MDS coexisting with β-thalassemia trait : A case report and literature review focused on diagnostic distinction from acquired β-thalassemia
    Zenghui Fang, Lu Chen, Menghe Zhao +1
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Comments on “surface-based brain age index reflects hematological impacts on cognitive development in children with beta-thalassemia major”
    iSciencePeer-reviewedCC BY 4.0Human geneticsCell PressCrossref
BibTeX
@article{fernando2026genotypicphenotypic,
  title = {{Genotypic-Phenotypic Correlations in Non-HbE β-Thalassemia Intermedia: A Geographic Systematic Review.}},
  author = {Kavindya Fernando and Shiromi Perera and Anuja Premawardhena},
  journal = {Molecular genetics \& genomic medicine},
  year = {2026},
  month = nov,
  doi = {10.1002/mgg3.70330},
  url = {https://europepmc.org/article/MED/42973095},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Genotypic-Phenotypic Correlations in Non-HbE β-Thalassemia Intermedia: A Geographic Systematic Review.
AU  - Kavindya Fernando
AU  - Shiromi Perera
AU  - Anuja Premawardhena
PY  - 2026
DA  - 2026/11/01
JO  - Molecular genetics & genomic medicine
DO  - 10.1002/mgg3.70330
UR  - https://europepmc.org/article/MED/42973095
AB  - Background  β-thalassemia intermedia (β-TI), now more commonly classified within the spectrum of non-transfusion-dependent thalassemia (NTDT), is a clinically heterogeneous disorder in which disease severity is determined not only by β-globin mutations but also by co-inherited genetic modifiers that vary across populations. These include α-globin gene alterations, fetal haemoglobin (HbF)-inducing polymorphisms, and other regulatory loci that influence globin chain balance.Methods  A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed was searched from inception to May 2026, supplemented by citation tracking and manual screening. Studies reporting genotype-phenotype correlations in β-TI were included. Data were synthesized qualitatively by geographic region.Results  Twenty-one studies were included. The available evidence suggests Mediterranean populations are primarily influenced by mild β-globin mutations. In Middle Eastern populations, HbF-inducing polymorphisms, particularly the XmnI variant, played a prominent role, often mitigating severe genotypes. Among the included studies, Asian populations exhibited the greatest molecular heterogeneity, with α-globin gene dosage alterations, including triplication, contributing substantially to disease expression.Conclusion  The available evidence suggests regional differences in the contribution of genetic modifiers to the β-thalassemia intermedia phenotype. Recognition of these patterns may improve understanding of genotype-phenotype variability and may help inform future approaches to diagnosis, prognostication, and individualized therapeutic strategies.
SN  - 2324-9269
ER  -